Seeking Alpha

Mike Zaman's  Instablog

Mike Zaman
Send Message
  • Avanir Pharmaceuticals (AVNR) Upgraded, Marchex (MCHX) Solid Numbers, AstraZeneca (AZN) Spurns Takeover Bid 0 comments
    May 2, 2014 9:43 AM | about stocks: AVNR, MCHX, AZN

    http://static.cdn-seekingalpha.com/uploads/2014/5/2/saupload_avnr.jpg Avanir Pharmaceuticals, Inc. (NASDAQ:AVNR)

    AVNR was upgraded from Neutral to Buy and its price target raised from $5.00 to $10.00 per share by brokerage firm Mizuho

    A couple of days ago, AVNR reported that the U.S. District Court for the District of Delaware has ruled in favor of the company in its patent infringement lawsuit against Par Pharmaceuticals, Inc. and Impax Laboratories, Inc. in conjunction with their Abbreviated New Drug Applications for generic versions of NUEDEXTA(NYSE:R) (dextromethorphan hydrobromide/quinidine sulfate) capsules for the treatment of pseudobulbar affect.

    The ruling protects AVNR's NUEDEXTA patents through 2026, and prevents Par or Impax from bringing a biosimilar to market.

    Pseudobulbar affect (NYSE:PBA) is a neurologic condition characterized by emotional outbursts that are often contrary or exaggerated to the patient's inner mood state, causing them to laugh or cry uncontrollably. As a result, many of those afflicted with PBA show significant impairment on standard measures of health status, and disruption in occupational and social function, often leading to social isolation.

    PBA can occur in stroke survivors or people with other neurologic conditions such as dementia, multiple sclerosis, Lou Gehrig's disease (ALS) or traumatic brain injury. It is thought to affect more than 1 million people in the U.S.

    According to AVNR, new data from the Phase III STAR Trial showed that NUEDEXTA may provide early PBA symptomatic remission. Throughout the trial, sustained episode remission rates in patients treated with NUEDEXTA were significantly higher compared to placebo.

    AVNR's NUEDEXTA is the only medication specifically designed and FDA-approved to treat PBA.

    http://static.cdn-seekingalpha.com/uploads/2014/5/2/saupload_avnrch.png

    AVNR is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

    More about Avanir Pharmaceuticals, Inc. (AVNR) at www.avanir.com.

    **

    http://static.cdn-seekingalpha.com/uploads/2014/5/2/saupload_mchx.jpg Marchex, Inc. (NASDAQ:MCHX)

    For the first quarter 2014, MCHX posted GAAP revenue of $50.5 million, compared to $34.7 million in the same period the prior year, GAAP net income from continuing operations of $846,000, versus $116,000 for the first quarter of 2013, and GAAP net income from continuing operations attributable to common stockholders per diluted share of $0.02, compared to $0.00 in the first quarter ended March 31, 2013.

    http://static.cdn-seekingalpha.com/uploads/2014/5/2/saupload_mchsch.png

    MCHX is a mobile advertising technology company. It provides a suite of products and services for businesses that depend on consumer phone calls to drive sales. MCHX's mobile advertising platform delivers new customer phone calls to businesses, while its technology analyzes the data in these calls to help maximize ad campaign results.

    More about Marchex, Inc. (MCHX) at www.marchex.com

    **

    http://static.cdn-seekingalpha.com/uploads/2014/4/21/saupload_azn.jpg AstraZeneca PLC (NYSE:AZN)

    The board of directors of AZN rejected Pfizer's $106 billion takeover bid just hours after it was levelled, describing it as inadequate.

    Pfizer offered 50 pounds ($84.47) a share in cash and stock. The offer was a 7.3 increase on a previous bid of $100 billion..

    http://static.cdn-seekingalpha.com/uploads/2014/5/2/saupload_aznch.png

    AZN is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

    More about AstraZeneca PLC (AZN) at www.astrazeneca.com.

    **

    Read Full Disclaimer at www.pennyomega.com/disclaimer

    Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Back To Mike Zaman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.